Danaher (DHR) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Preliminary results and financial performance

• Fourth quarter 2024 revenues were essentially flat, exceeding expectations, with Bioprocessing in line and Diagnostics and Life Sciences slightly above forecasts due to higher respiratory sales at Cepheid.

• Adjusted operating profit margin was consistent with prior guidance, with strong operational performance offset by foreign exchange headwinds.

• Portfolio transformation since 2018 led to a shift from five segments to three, with $7.6 billion in revenue exited and $6 billion acquired, improving growth, gross and operating profit margins, and increasing operating cash flow above $6 billion.

• Recurring revenue profile improved from 50% in 2018 to around 80% in 2024, with operating profit margins rising from 20% to 30%.

• 2024 estimated total revenue reached ~$24B, with strong contributions from biotechnology, life sciences, and diagnostics.

Market positioning and growth drivers

• Focused on attractive end markets: pharma, biopharma, molecular and clinical diagnostics, and select applied markets, supported by strong secular growth drivers like aging population, biologics pipeline, and new technology adoption.

• Large installed bases and razor blade business models drive high-value consumables and recurring revenue.

• Leading PCR point-of-care molecular testing and exposure to cell and gene therapy trends position the company for future growth.

• Strategic end-market exposure includes pharma, biopharma, clinical diagnostics, and research, with differentiated business models and high recurring revenue.

• DBS enables differentiated execution and scale, supporting sustainable value creation.

Segment performance and innovation

• Bioprocessing is the largest Biotechnology segment, with ~$6 billion revenue and over 75% from monoclonal antibodies; Cytiva supports over 90% of global monoclonal antibody manufacturing volumes.

• Cytiva offers a broad and deep portfolio supporting various modalities, including cell, gene, and mRNA therapies.

• Life Sciences segment ($7.3 billion) has differentiated positions in genomics, proteomics, and analytical instrumentation, with over 60% recurring revenue.

• Diagnostics segment ($10 billion) led by Cepheid, with the largest installed base and FDA-approved menu; specialty diagnostics like Leica Biosystems and Radiometer expected to grow high single digits.

• Beckman Coulter Diagnostics relaunched its product lineup, supporting mid-single-digit plus growth; $1.5 billion invested in R&D annually.